Epilepsy Study
Zydus Lifesciences launches generic anti-epilepsy drug in US market
Zydus Lifesciences on Friday said it has launched generic epilepsy treatment medication in the US market. Zydus Pharmaceuticals (USA) Inc, a unit of the company, has launched Topiramate extended-release capsules in the American market. The company had earlier received final approval from the US Food and Drug Administration (USFDA) to market the product in strengths of USP 25 mg, 50 mg, and 100 mg, Zydus Lifesciences said in a statement. Zydus is the first company to receive final approval and launch the medication in the above mentioned strengths, it added. Topiramate extended-release capsules are indicated for epilepsy: initial monotherapy in patients who are six years of age and older with partial onset or primary generalized tonic-clonic seizures. It is also indicated for prophylaxis of migraine in patients 12 years of age and older. As per IQVIA data, Topiramate extended-release capsule had annual sales of USD 488 million in the US.
 "Zydus Lifesciences launches generic anti-epilepsy drug in US market")
Zydus Cadila gets USFDA tentative nod for epilepsy treatment drug
Zydus Cadila on Monday said it has received tentative approval from the US health regulator to market epilepsy treatment drug Brivaracetam tablets.
 "Zydus Cadila gets USFDA tentative nod for epilepsy treatment drug")
Epilepsy associated with brain volume, thickness differences: Study
The largest-ever neuroimaging study of people with epilepsy shows that epilepsy involves more widespread physical differences than previously assumed
 "Epilepsy associated with brain volume, thickness differences: Study")
